Abstract: Novel peptides that bind to the human transferrin receptor (hTfR) are provided. The peptide is a peptide comprising an amino acid sequence described in Ala-Val-MePhe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-K(MePEG4c)-Arg-Phe-MeTyr-Cys (SEQ ID NO: 1), or the peptide comprising one or more predetermined substitutions in the amino acid sequence described in SEQ ID NO:1.

Abstract: An object of the present invention is to provide a method for producing a peptide with high efficiency, and a method for producing a peptide which comprises the following steps (1) and (2): (1) a step of mixing an N-protected amino acid or an N-protected peptide with a carboxylic acid halide represented by the formula (I) (wherein X represents a halogen atom, R1, R2 and R3 each independently represent an aliphatic hydrocarbon group which may have a substituent, and a total number of the carbon atoms in R1, R2 and R3 is 3 to 40); and (2) a step of mixing the product obtained in the step (1) and a C-protected amino acid or a C-protected peptide is provided.

Abstract: [Problem] To provide a novel peptide having a BMP4 binding ability. [Solution] The present invention pertains to a peptide and a peptide-containing agent. The peptide according to the present invention has an amino acid sequence of E-R-V-F4COO-Atp-D-R-Bph-P-Y-P-Bph-Y-F4COO-F4COO-S-C (SEQ ID NO: 1) or has an amino acid sequence resulting from substitution, addition, deletion, or insertion at 1-15 amino acid residues selected from the group consisting of amino acid residues at positions 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and 16 in said amino acid sequence.

Abstract: [Problem] To provide a peptide complex capable of binding to c-Met protein. [Solution] Provided is a peptide complex containing a peptide A, in which the peptide A is a peptide comprising the amino acid sequence represented by X1-X2-X3-V-S-X4-D-X5-D-X6-P-R-W-X7-MeC (SEQ ID NO: 1) or comprises an amino acid sequence having such a structure that 1 to 3 amino acid residues are substituted, deleted, added or inserted in the amino acid sequence represented by SEQ ID NO: 1. X1 represents A, MeA, F or MeF. X2 represents V, T, E, Q or W. X3 represents A, R, Y or D. X4 represents F, MeF, L or MeF. X5 represents D, E, S, P or V. X6 represents(S)-2-aminoheptanoic acid (Ahp), R,L-norleucine (Nle), (S)-2,7-diaminoheptanoic acid (Hty) or S. X7 represents S,A,L-?-aminobutanoic acid (Abu), D, Q or V.

Abstract: The present technology generally relates to peptides that bind to the growth hormone receptor (GhR), to peptides that bind to the GhR and have antagonistic activity, and to compositions comprising such peptides.

Abstract: A peptide, compound, or conjugate that can bind CD38. The CD38-binding peptide, compound, or conjugate has a sequence selected from the group consisting of SEQ ID NOs. 1-34. The CD38-binding peptides, compounds, or conjugates are useful for treating CD38-associated conditions, disorders, or diseases, such as cancer, leukemia, or myelomas.

Abstract: The present invention provides a cyclic peptide represented by formula (I) [wherein A is selected from the ring-forming groups A1 to A5; Xaa1 is a residue of an aromatic amino acid; Xaa2 is a residue of an aromatic amino acid, a basic amino acid, or an aliphatic amino acid; Xaa3 and Xaa8 each have a structure independently selected from a residue of an amino acid represented by formula (III) or (III?) in which thiol groups of Xaa3 and Xaa8 form a bond; Xaa4 is a residue of a neutral amino acid; Xaa5 is a residue of a basic amino acid; Xaa6 is a residue of a neutral amino acid or an acidic amino acid; Xaa7 is a residue of an aromatic amino acid; Xaa9 is a residue of an aromatic amino acid, an aliphatic amino acid, or a basic amino acid; Xaa10 is a residue of an aromatic amino acid; and Xaa11 is a residue of an aliphatic amino acid], or a pharmaceutically acceptable salt thereof.

Abstract: [Problem to be solved] To provide a compound having markedly higher antiviral activity than iHA 100, an intermediate for producing the compound, and a medical drug, or the like, containing the high-activity compound above. [Solution] The invention relates to a hemagglutinin-binding peptide, a pharmaceutically acceptable salts, or a solvate thereof, the hemagglutinin-binding peptide being: (1) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2: Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys (SEQ ID NO: 1), Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys-Lys (SEQ ID NO: 2), or the like.

Abstract: The present invention is to provide a method for producing a peptide containing an N-alkylamino acid, which comprises the following Steps (1) to (3). Step (1): a step of mixing an N-terminal protected amino acid or an N-terminal protected peptide with a carboxylic acid halide or a halogenated alkyl formate; Step (2): a step of mixing an amino acid or a peptide in which the N-terminal and the C-terminal are not protected with a trialkylsilylating agent; and Step (3): a step of mixing the product obtained in Step (1) with the product obtained in Step (2).

Abstract: The technic to pass through the blood-brain barrier is provided.

Abstract: [Problem to be solved] To provide a compound having markedly higher antiviral activity than iHA 100, an intermediate for producing the compound, and a medical drug, or the like, containing the high-activity compound above. [Solution] The invention relates to a hemagglutinin-binding peptide, a pharmaceutically acceptable salts, or a solvate thereof, the hemagglutinin-binding peptide being: (1) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2: Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys (SEQ ID NO: 1), Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys-Lys (SEQ ID NO: 2), or the like.

Abstract: The invention provides a method for producing a peptide which comprises the following steps (1) and (2): (1) a step of condensing a C-protected amino acid or a C-protected peptide to a C-terminal of an N-protected amino acid or an N-protected peptide represented by the formula (I): wherein Y represents an amino acid in which a C-terminal is unprotected or a peptide in which a C-terminal is unprotected, R1, R2 and R3 each independently represent an aliphatic hydrocarbon group which may have a substituent(s), a total number of the carbon atoms in the R1R2R3Si group is 10 or more, and the R1R2R3SiOC(O) group is bonded to the N-terminal in Y, and (2) a step of removing the protective group at the C-terminal of the peptide obtained in step (1).

Abstract: Provided are linkers suitable for preparing a conjugate of a nucleic acid and a peptide as a translation product thereof in a reconstituted cell-free translation system in genotype-phenotype mapping (display methods), said linkers comprising a single-stranded structure region having a side chain base pairing with the base at the 3?-end of an mRNA at one end and a peptidyl acceptor region containing an amino acid attached to an oligo RNA consisting of a nucleotide sequence of ACCA via an ester bond at the other end, characterized in that the ester bond is formed by using an artificial RNA catalyst. Also provided are display methods using [mRNA]-[linker]-[peptide] conjugates assembled via such linkers.

Abstract: [Problem] To provide a guanidine derivative (in particular, an amino acid compound having a 4-guanidino group) which has a low production cost and is less likely to cause the problem of waste liquor, a method for producing the same and an intermediate to be used in the production of the same. [Solution] A compound represented by formula (I), a tautomer thereof, an enantiomer thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof; a method for producing a compound represented by formula (I), a tautomer thereof, an enantiomer thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, said method comprising a mixing step for mixing a compound represented by formula (II) with a compound represented by formula (III); and a compound represented by formula (IV) or formula (V).

Abstract: To provide a peptide, etc., capable of passing through the blood-brain barrier (BBB) by binding to a human transferrin receptor (hTfR). A peptide, etc., having the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys) or an amino acid sequence having substitutions, deletions, additions, and/or insertions of 1 to 10 amino acid residues (inclusive) in the amino acid sequence shown in SEQ ID NO: 1.

Abstract: An object of the present invention is to provide a method for producing a peptide with high efficiency, and a method for producing a peptide which comprises the following steps (1) and (2): (1) a step of mixing an N-protected amino acid or an N-protected peptide with a carboxylic acid halide represented by the formula (I) (wherein X represents a halogen atom, R1, R2 and R3 each independently represent an aliphatic hydrocarbon group which may have a substituent, and a total number of the carbon atoms in R1, R2 and R3 is 3 to 40); and (2) a step of mixing the product obtained in the step (1) and a C-protected amino acid or a C-protected peptide is provided.

Abstract: The present invention is to provide a method for producing a peptide containing an N-alkylamino acid, which comprises the following Steps (1) to (3). Step (1): a step of mixing an N-terminal protected amino acid or an N-terminal protected peptide with a carboxylic acid halide or a halogenated alkyl formate; Step (2): a step of mixing an amino acid or a peptide in which the N-terminal and the C-terminal are not protected with a trialkylsilylating agent; and Step (3): a step of mixing the product obtained in Step (1) with the product obtained in Step (2).

Abstract: The invention provides a method for producing a peptide which comprises the following steps (1) and (2): (1) a step of condensing a C-protected amino acid or a C-protected peptide to a C-terminal of an N-protected amino acid or an N-protected peptide represented by the formula (I): wherein Y represents an amino acid in which a C-terminal is unprotected or a peptide in which a C-terminal is unprotected, R1, R2 and R3 each independently represent an aliphatic hydrocarbon group which may have a substituent(s), a total number of the carbon atoms in the R1R2R3Si group is 10 or more, and the R1R2R3SiOC(O) group is bonded to the N-terminal in Y, and (2) a step of removing the protective group at the C-terminal of the peptide obtained in step (1).

Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.

Abstract: A method for producing a peptide by conducting steps (1) condensing an N-protected amino acid or an N-protected peptide to an N-terminus of a C-protected amino acid or a C-protected peptide represented by formula (II): wherein Y represents an amino acid or a peptide with an unprotected N-terminus; R1, R2 and R3 each independently represent an optionally substituted aliphatic hydrocarbon group, an optionally substituted aromatic hydrocarbon group, or —OR4 (wherein R4 represents an optionally substituted aliphatic or aromatic hydrocarbon group; two of R1, R2 and R3 may form a 5- to 7-membered ring together with the Si atom to which they are bonded; and the R1R2R3Si group has 8 or more carbon atoms and is bonded to a C-terminus of an amino acid or a peptide in Y, and (2) removing the protective group at the N-terminus of the peptide obtained in step (1).